Skip to content
Rowan Street Capital recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Fund posted a return of 43.2% for the quarter (gross), outperforming its benchmark, the S&P 500 Index which returned 20.5% in the same quarter. You should check out Rowan Street Capital’s top 5 stock picks for […]...
If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly......
Every investor in Cisco Systems, Inc. (NASDAQ:CSCO) should be aware of the most powerful shareholder groups......
Sevens Report Research Founder Tom Essaye speaks with Yahoo Finance’s Alexis Christoforous, Brian Sozzi and Jared Blikre about the latest market moves....
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to......
(Bloomberg) -- A coronavirus vaccine the University of Oxford is developing with AstraZeneca Plc showed promising results in early human testing, a sign of progress in the high-stakes pursuit of a shot to defeat the pathogen.The vaccine increased levels of both protective neutralizing antibodies and immune T-cells that target the virus, according to the study organizers. The results were published Monday in The Lancet medical journal.AstraZeneca shares rose as much as 10% in London.“We are seeing very good immune responses, not just on neutralizing antibodies but of T-cells as well,” said Adrian Hill, head of Oxford’s Jenner Institute, in an interview. “We’re stimulating both arms of the immune system.”The results will be closely scrutinized as governments around the world seek to end a pandemic that’s killed more than 600,000 people and triggered economic turmoil since erupting earlier this year. Moderna Inc., another front-runner, released results last week from an early-stage test...
